139 related articles for article (PubMed ID: 38738869)
21. Cost effectiveness of trastuzumab in the adjuvant treatment of early breast cancer: a lifetime model.
Millar JA; Millward MJ
Pharmacoeconomics; 2007; 25(5):429-42. PubMed ID: 17488140
[TBL] [Abstract][Full Text] [Related]
22. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant Trastuzumab in HER2-Positive Early Breast Cancer by Age and Hormone Receptor Status: A Cost-Utility Analysis.
Leung W; Kvizhinadze G; Nair N; Blakely T
PLoS Med; 2016 Aug; 13(8):e1002067. PubMed ID: 27504960
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of trastuzumab as adjuvant therapy for early breast cancer: a systematic review.
Chan AL; Leung HW; Lu CL; Lin SJ
Ann Pharmacother; 2009 Feb; 43(2):296-303. PubMed ID: 19193576
[TBL] [Abstract][Full Text] [Related]
25. Cost-Effectiveness of Trastuzumab With or Without Chemotherapy as Adjuvant Therapy in HER2-Positive Elderly Breast Cancer Patients: A Randomized, Open-Label Clinical Trial, the RESPECT Trial.
Takumoto Y; Shiroiwa T; Shimozuma K; Iwata H; Takahashi M; Baba S; Kobayashi K; Hagiwara Y; Kawahara T; Uemura Y; Mukai H; Taira N; Sawaki M
Clin Drug Investig; 2022 Mar; 42(3):253-262. PubMed ID: 35233755
[TBL] [Abstract][Full Text] [Related]
26. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer.
Candon D; Healy J; Crown J
Acta Oncol; 2014 Feb; 53(2):201-8. PubMed ID: 24125103
[TBL] [Abstract][Full Text] [Related]
27. The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer.
Garrison LP; Veenstra DL
Value Health; 2009; 12(8):1118-23. PubMed ID: 19624617
[TBL] [Abstract][Full Text] [Related]
28. A global economic model to assess the cost-effectiveness of new treatments for advanced breast cancer in Canada.
Beauchemin C; Letarte N; Mathurin K; Yelle L; Lachaine J
J Med Econ; 2016 Jun; 19(6):619-29. PubMed ID: 26850287
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
[TBL] [Abstract][Full Text] [Related]
30. An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.
Gogate A; Rotter JS; Trogdon JG; Meng K; Baggett CD; Reeder-Hayes KE; Wheeler SB
Breast Cancer Res Treat; 2019 Apr; 174(2):343-355. PubMed ID: 30603995
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.
Zhang H; Zhang Y; Huang C; Wang J
Clin Drug Investig; 2021 Jun; 41(6):569-577. PubMed ID: 33876415
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness analysis of 1st through 3rd line sequential targeted therapy in HER2-positive metastatic breast cancer in the United States.
Diaby V; Adunlin G; Ali AA; Zeichner SB; de Lima Lopes G; Kohn CG; Montero AJ
Breast Cancer Res Treat; 2016 Nov; 160(1):187-196. PubMed ID: 27654970
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness Analysis of Ado-trastuzumab Emtansine (T-DM1) for the Adjuvant Treatment of Patients With Residual Invasive HER2+ Early Breast Cancer in the United States.
Sussell J; Singh Jhuti G; Antao V; Herrera-Restrepo O; Wehler E; Bilir SP
Am J Clin Oncol; 2021 Jul; 44(7):340-349. PubMed ID: 34151896
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness analyses of breast cancer medications use in developing countries: a systematic review.
Al-Ziftawi NH; Shafie AA; Mohamed Ibrahim MI
Expert Rev Pharmacoecon Outcomes Res; 2021 Aug; 21(4):655-666. PubMed ID: 32657174
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada.
Attard CL; Pepper AN; Brown ST; Thompson MF; Thuresson PO; Yunger S; Dent S; Paterson AH; Wells GA
J Med Econ; 2015 Mar; 18(3):173-88. PubMed ID: 25347449
[TBL] [Abstract][Full Text] [Related]
36. Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Squires H; Pandor A; Thokala P; Stevens JW; Kaltenthaler E; Clowes M; Coleman R; Wyld L
Pharmacoeconomics; 2018 Jan; 36(1):29-38. PubMed ID: 28770452
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant trastuzumab chemotherapy in early breast cancer: meta-analysis of randomised trials and cost-effectiveness analysis.
Doan TN; Barendregt J
Swiss Med Wkly; 2019 May; 149():w20082. PubMed ID: 31104310
[TBL] [Abstract][Full Text] [Related]
38. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore.
Cheng LJ; Loke L; Lim EH; Pearce F; Aziz MIA; Ng K
Expert Rev Pharmacoecon Outcomes Res; 2021 Jun; 21(3):449-456. PubMed ID: 33595372
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil.
Botelho CH; Estevez-Diz MDP; Campolina AG
Expert Rev Pharmacoecon Outcomes Res; 2022 Jan; 22(1):63-72. PubMed ID: 34319216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]